Róisín Shortall (Dublin North West, Social Democrats)
Link to this: Individually | In context | Oireachtas source

868. To ask the Minister for Health if his attention has been drawn to reports that sotrovimab is less effective against the BA.2 subvariant of Covid-19; the engagements he has had with the European Medicines Agency and the manufacturer regarding this issue; and if he will make a statement on the matter. [18231/22]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The Department of Health continues to monitor the evidence relating to prevention and treatment options for COVID-19, as it has done throughout the pandemic, in order to protect and optimise outcomes for the Irish population, particularly those at high risk of severe disease. As part of this process, there is regular communication with relevant agencies including, but not limited to, the European Medicines Agency, the Health Products Regulatory Authority, and drug manufacturers, in addition to an ongoing review of the evidence-base supporting current and potential therapeutics. 

Sotrovimab has demonstrated strong results in reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at high risk of developing severe disease, and in Ireland this medication has provided protection to such individuals since January of this year.

The Department is closely monitoring emerging data in relation to Sotrovimab efficacy against all variants, including the BA.2 subvariant, and both in vitro and in vivo efficacy data, as well as any potential changes, including dosing changes, that may be advised. 

The recent publication of the WHO's third strategic preparedness, readiness and response plan, available at www.who.int/publications/m/item/strategic-preparedness-readiness-and-response-plan-to-end-the-global-covid-19-emergency-in-2022  highlights the expected continued evolution of the virus and the likelihood of new variants, to which we must be able to rapidly respond to ensure that the most vulnerable are protected.

All individuals are strongly encouraged to attend for vaccination, including those that are eligible for a fourth booster dose.